SCHEMBL2115432

SCHEMBL2115432

C[C@H](N)c1cc2ccc(F)cc2nc1N1CCNC(=O)C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 4/20 0.38
AOC3 Q16853 1/20 0.38
OPRK1 P41145 3/20 0.38
OPRM1 P35372 2/20 0.38
OGFRL1 Q5TC84 2/20 0.38
OPRD1 P41143 1/20 0.38
PRKCH P24723 1/20 0.38
PRKCE Q02156 1/20 0.38
KDM4E B2RXH2 1/20 0.37
SCN9A Q15858 1/20 0.37
CACNG2 Q9Y698 1/20 0.36
DPP4 P27487 1/20 0.35
SOS1 Q07889 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2115435 1.00 GRIA1 (0.38) GRIA1AOC3OPRK1OPRM1OGFRL1
SCHEMBL2115290 0.84 PRKCH (0.37) GRIA1AOC3OPRK1OPRM1OGFRL1
SCHEMBL2115287 0.84 PRKCH (0.37) GRIA1AOC3OPRK1OPRM1OGFRL1
SCHEMBL14480681 0.81 SOS1 (0.37) GRIA1OPRK1OPRM1OGFRL1OPRD1
SCHEMBL14480684 0.81 SOS1 (0.37) GRIA1OPRK1OPRM1OGFRL1OPRD1
SCHEMBL2113571 0.77 DPP4 (0.36) GRIA1AOC3OPRK1PRKCHPRKCE
SCHEMBL2113563 0.77 DPP4 (0.36) GRIA1AOC3OPRK1PRKCHPRKCE
SCHEMBL716475 0.76 PIK3CD (0.40) OPRK1OPRM1OGFRL1OPRD1PRKCH
SCHEMBL717871 0.76 PRKCH (0.38) GRIA1OPRK1OPRM1OGFRL1OPRD1
SCHEMBL717872 0.76 PRKCH (0.38) GRIA1OPRK1OPRM1OGFRL1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors UCB PHARMA S.A. (BE) 2012-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120095005-A1 Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors PI4KA, PDPK1, PIK3CA GRIA1 647/4885AOC3 1957/4885OPRK1 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.